EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control

Susana Luengo-Arias iD, Carmen Domínguez-Alonso, Ivana Zagorac iD, Antonio Tapia-Galisteo iD, Eva García-Veros iD, Laura Rubio-Pérez iD, Marina Gómez-Rosel iD, Patricia Fuentes iD, Patricia Hernández-López iD, Óscar Aguilar-Sopeña iD, Laura Almagro-Puente iD, Sonia Martínez-González iD and 12 more

Advanced Science · 2026-11 · 13 (61)

DOI: 10.1002/advs.77236 ↗

At a glance

Journal article in Advanced Science, published online on 2026-08-24. Written by Susana Luengo-Arias and 23 co-authors. Institution: Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain. Major MEDLINE topics: Immunotherapy, T-Lymphocytes. 61 references. The full text is freely available (open access, CC BY 4.0). Funded by: MCIN/AEI/10.13039/501100011033, Carlos III Health Institute (ISCIII) with European Regional Development Fund (FEDER), Asociación Española contra el Cáncer (AECC).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Living cell therapies lack robust, reversible mechanisms for externally controlling therapeutic activity after administration, limiting their safety and clinical adaptability. Here we engineer a drug‐gated cellular immunotherapy platform in which T cells function as programmable factories that secrete two inactive antibody modules whose extracellular assembly into a functional bispecific T cell engager (TCE) is controlled by a small‐molecule input. Using a rapalog‐inducible FKBP‐FRB* heterodimerization switch, we design a split CD19 × CD3 engager architecture that remains inactive in the absence of drug and assembles on demand upon rapalog exposure. A 2A‐peptide bicistronic construct enables coordinated expression and secretion of both modules, allowing precise drug‐dependent control of TCE formation in situ. Drug administration quantitatively regulates T cell activation and cytotoxicity against CD19 + targets in vitro, with stringent OFF‐state behavior in the absence of rapalog. In xenograft models, systemic rapalog administration induces on‐demand anti‐tumor activity without evidence of treatment‐related toxicity, demonstrating reversible pharmacological control of a locally secreted therapeutic interface. We further extend this strategy to an EGFR‐targeting TCE, demonstrating the modularity and broad adaptability of the platform across distinct antigen specificities. This work introduces a generalizable engineering framework for externally programmable cell therapies, enabling tunable, safety‐by‐design control of T cell‐based immunotherapies.

Subjects

MeSH terms (MEDLINE)

ImmunotherapyT-LymphocytesAnimalsHumansMiceLymphocyte Activation

Author keywords

STAbT cell engagershematological malignanciesrapalogswitchable TCE

Authors and institutions

  • Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • CNIO-HMRIB Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Centro de Biología Molecular (CBM) Severo Ochoa CSIC-UAM, Madrid, Spain.
  • Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, Madrid, Spain.
  • Lymphocyte Immunobiology Group, Instituto De Investigación Sanitaria 12 De Octubre (imas12), Madrid, Spain.

ORCID profiles: Susana Luengo-Arias, Ivana Zagorac, Antonio Tapia-Galisteo, Eva García-Veros, Laura Rubio-Pérez, Marina Gómez-Rosel, Patricia Fuentes, Patricia Hernández-López, Óscar Aguilar-Sopeña, Laura Almagro-Puente, Sonia Martínez-González, Lucía Cañizares-Moscato, María Rivas-Sánchez, Belén Blanco, Ángel Ramírez-Fernández, Laura Díez-Alonso, Carmen Blanco-Aparicio, Javier Arroyo-Ródenas, Jorge Martínez-Torrecuadrada, María L Toribio, Anaïs Jiménez-Reinoso, Luis Álvarez-Vallina

Funding

  • MCIN/AEI/10.13039/501100011033
  • Carlos III Health Institute (ISCIII) with European Regional Development Fund (FEDER)
  • Asociación Española contra el Cáncer (AECC)
  • CRIS Cancer Foundation
  • Fundación "La Caixa"
  • Fundación para la Investigación Biomédica del Hospital 12 de Octubre
  • Fundación Fero
  • ISCIII

Cite

APA

Luengo-Arias, S., Domínguez-Alonso, C., Zagorac, I., Tapia-Galisteo, A., García-Veros, E., Rubio-Pérez, L., Gómez-Rosel, M., Fuentes, P., Hernández-López, P., Aguilar-Sopeña, Ó., Almagro-Puente, L., Martínez-González, S., Cañizares-Moscato, L., Rivas-Sánchez, M., Blanco, B., Ramírez-Fernández, Á., Díez-Alonso, L., Blanco-Aparicio, C., Arroyo-Ródenas, J., …, & Álvarez-Vallina, L. (2026). A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control. Advanced Science, 13(61). https://doi.org/10.1002/advs.77236

Vancouver

Luengo-Arias S, Domínguez-Alonso C, Zagorac I, Tapia-Galisteo A, García-Veros E, Rubio-Pérez L, et al. A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control. Advanced Science. 2026;13(61). doi:10.1002/advs.77236

BibTeX
@article{LuengoArias2026,
  author = {Luengo-Arias, Susana and Domínguez-Alonso, Carmen and Zagorac, Ivana and Tapia-Galisteo, Antonio and García-Veros, Eva and Rubio-Pérez, Laura and Gómez-Rosel, Marina and Fuentes, Patricia and Hernández-López, Patricia and Aguilar-Sopeña, Óscar and Almagro-Puente, Laura and Martínez-González, Sonia and Cañizares-Moscato, Lucía and Rivas-Sánchez, María and Blanco, Belén and Ramírez-Fernández, Ángel and Díez-Alonso, Laura and Blanco-Aparicio, Carmen and Arroyo-Ródenas, Javier and Martínez-Torrecuadrada, Jorge and Toribio, María L and Roda-Navarro, Pedro and Jiménez-Reinoso, Anaïs and Álvarez-Vallina, Luis},
  title = {A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {61},
  doi = {10.1002/advs.77236}
}
Start for free →